Jiangxi Rimag Group Co vs HCA Healthcare: Fair Value & Quality
Both stocks run through our valuation models. Here is how Jiangxi Rimag Group Co (2522) and HCA Healthcare (HCA) compare, as of Aug 13, 2026.
As of Aug 13, 2026, Fair Value Calculator sees HCA Healthcare as the more attractively valued of the two: Jiangxi Rimag Group Co trades at HK$4.66 versus a fair value of HK$2.51 (-46%), while HCA Healthcare trades at $411 versus $555 (+35%).
Jiangxi Rimag Group Co
2522.HK · HKD · Healthcare
-46%
upside to fair value
overvalued
PriceHK$4.66
Fair ValueHK$2.51
Quality43/100
HCA Healthcare
HCA · USD · Health Care
+35%
upside to fair value
undervalued
Price$411
Fair Value$555
Quality70/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Jiangxi Rimag Group CoHCA Healthcare
Valuation
462.0×P/E (TTM)12.5×
2.09×P/S (TTM)1.06×
0.92×P/B—
7.3×EV/EBITDA7.8×
—PEG1.18×
—Dividend yield0.8%
—Dividend per share$2.94
Profitability
0%Net margin9%
-4%Operating margin15%
-1%Return on equity136%
0%Return on assets12%
Growth
17%Revenue growth (YoY)4%
3.6%Avg. growth/yr (3Y)7.9%
—Avg. growth/yr (5Y)8.0%
Balance & size
0.08×Debt / equity—
$233MMarket cap$81B
healthyGrowth qualityhealthy
HCA Healthcare leads: 2 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Jiangxi Rimag Group Coof which business quality 46 · market factors 15HCA Healthcareof which business quality 66 · market factors 44
ProfitabilityMargins and returns on capital today
16
76
Quality GrowthAre margins and returns improving?
56
61
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
30
75
Low VolatilityCalm price path (market factor)
50
59
MomentumPrice trend over the last 3–12 months (market factor)
0
35
52W MomentumDistance to the 52-week high (market factor)
2
42
Net IssuanceBuybacks instead of dilution
59
100
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Jiangxi Rimag Group Co
DCF ModelsHK$3.67
Earnings-BasedHK$0.19
MultiplesHK$1.67
Asset-BasedHK$3.73
Growth DCFHK$3.62
Economic ProfitHK$2.76
Growth EarningsHK$0.17
20 of 24 models see the stock below the current price.
HCA Healthcare
DCF Models$546
Earnings-Based$289
Dividend Discount$53.85
Multiples$673
Growth DCF$540
Economic Profit$419
Growth Earnings$506
6 of 23 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Jiangxi Rimag Group Co
Bear HK$1.41Fair Value HK$2.51Bull HK$3.45
HK$4.66 = current price (white tick)
HCA Healthcare
Bear $270Fair Value $555Bull $841
$411 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Jiangxi Rimag Group Co · Healthcare
Quality score43 · below median
Fair value upside-46% · below median
HCA Healthcare · Health Care
Quality score70 · Top 25%
Fair value upside+35% · Top 25%
Bottom line
As of Aug 13, 2026, Fair Value Calculator sees HCA Healthcare as the more attractively valued of the two: Jiangxi Rimag Group Co trades at HK$4.66 versus a fair value of HK$2.51 (-46%), while HCA Healthcare trades at $411 versus $555 (+35%).
HCA Healthcare has the higher quality score (70/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
